A carregar...
Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
In type 2 diabetes (T2D), early combination therapy using agents that target a number of the underlying pathophysiologic defects contributing to hyperglycemia may improve patient outcomes. For many patients, the combination of metformin with a sodium–glucose cotransporter-2 (SGLT-2) inhibitor may be...
Na minha lista:
| Publicado no: | Diabetes Metab Syndr Obes |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4801192/ https://ncbi.nlm.nih.gov/pubmed/27042132 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S65588 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|